Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20548405 | 0.98 | KDM1A (0.63) | KDM1AALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL13458067 | 0.83 | DYRK1A (0.61) | KDM1AMAP4K4DYRK1ACLK4CYP3A4 | |
| SCHEMBL12019038 | 0.82 | KDM1A (0.58) | KDM1AALDH1A1KDM4EHSD17B10MAP4K4 | |
| SCHEMBL2406613 | 0.81 | KDM1A (0.57) | KDM1AMAP4K4DYRK1ACLK4MAPT | |
| SCHEMBL2643818 | 0.81 | KDM1A (0.53) | KDM1AALDH1A1KDM4EKMT2AMAP4K4 | |
| SCHEMBL16835818 | 0.81 | CYP11B1 (0.48) | KDM1AALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL27785384 | 0.80 | DYRK1A (0.69) | KDM1AALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL1551351 | 0.80 | RXFP1 (0.57) | ALDH1A1KDM4EKMT2AMEN1BRCA1 | |
| SCHEMBL27783058 | 0.79 | MAP4K4 (0.55) | ALDH1A1KDM4EKMT2AMEN1MAP4K4 | |
| SCHEMBL20924173 | 0.79 | KDM1A (0.70) | KDM1AMAP4K4DYRK1ACLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802492-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-11-06 | — | — | EP | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | disclosed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | disclosed |
| EP-3802492-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | Oxford University Innovation Limited (GB) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019234405-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019234405-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-12-12 | — | — | WO | disclosed |
| EP-3042658-B1 | MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE | UNIV KYOTO (JP) | 2019-01-16 | — | — | EP | disclosed |
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| US-9573887-B2 | Naphthalene derivative | DAITO CHEMIX CORPORATION (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2623494-B1 | AGENT FOR TREATMENT OF EYE DISEASES | DAITO CHEMIX CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | disclosed |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | KYOTO UNIVERSITY (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2623494-A1 | AGENT FOR TREATMENT OF EYE DISEASES | Daito Chemix Corporation (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130184241-A1 | Naphthalene Derivative | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2599771-A1 | NAPHTHALENE DERIVATIVE | Daito Chemix Corporation (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | KRAS, NRAS, HRAS | KDM1A 4271/4885ALDH1A1 2940/4885KDM4E 4050/4885 |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | KRAS, NRAS, HRAS | KDM1A 4271/4885ALDH1A1 2940/4885KDM4E 4050/4885 |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | KDM1A 3077/4885ALDH1A1 3024/4885KDM4E 2371/4885 |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | KDM1A 1919/4885ALDH1A1 109/4885KDM4E 1861/4885 |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | PDE6A, ALDH1A2, PDE6D | KDM1A 2973/4885ALDH1A1 695/4885KDM4E 3996/4885 |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | KDM1A 1919/4885ALDH1A1 109/4885KDM4E 1861/4885 |
| US-20130184241-A1 | Naphthalene Derivative | VCP, NOC2L, VAT1 | KDM1A 1691/4885ALDH1A1 1402/4885KDM4E 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.